Moxaverine
Appearance
(Redirected from ATC code A03AD30)
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.031.003 |
Chemical and physical data | |
Formula | C20H21NO2 |
Molar mass | 307.393 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Moxaverine has been used in therapy based on the direct vasodilatory effect of the drug, a phosphodiesterase inhibitor,[1] and on its influence on the rheological properties of red blood cells.[2]
Moxaverine hydrochloride (Kollateral forte®, Ursapharm. Saarbrücken, Germany) has been shown to increase ocular blood flow in patients with age-related macular degeneration, primary open angle glaucoma, and to increase choroidal and retrobulbar blood flow in elderly patients with eye diseases associated with hypo-perfusion.[3] The ocular efficacy of moxaverine has been explored in the clinic.[4]
References
[edit]- ^ Mannhold R (December 1988). "Inhibition of calmodulin dependent c-AMP-phosphodiesterase by moxaverine and papaverine". Arzneimittel-Forschung. 38 (12): 1806–8. PMID 2854468.
- ^ Schmid-Schönbein H, Schröder S, Grebe R, Artmann G, Eschweiler H, Teitel P (May 1988). "Influence of moxaverine hydrochloride on membrane curvature and microsieve filterability of red cells after exposure to hyperosmolarity and lactacidosis". Arzneimittel-Forschung. 38 (5): 710–6. PMID 3415714.
- ^ Pemp B, Garhofer G, Lasta M, Schmidl D, Wolzt M, Schmetterer L (March 2012). "The effects of moxaverine on ocular blood flow in patients with age-related macular degeneration or primary open angle glaucoma and in healthy control subjects". Acta Ophthalmologica. 90 (2): 139–45. doi:10.1111/j.1755-3768.2010.01878.x. PMID 20456253. S2CID 3269602.
- ^ Clinical trial number NCT01629680 for "A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects" at ClinicalTrials.gov